Voxcan’s preclinical excellence pushes again a new osteoarthritic knee pain candidate to clinical trials

The JTA-004 trial has been approved by regulatory authorities in Denmark

At the frame of a strategic collaboration between Voxcan and Bone therapeutics, Voxcan played a key role in the characterization of a new PrimOA animal model of osteoarthritis by antero cruciate ligament transection (ACLT). The objective of this collaboration was to develop a relatively representative model of the human disease, to monitor the model using CT scan and to study the effectiveness of the new treatment JTA-004 targeting osteoarthritic knee pain.

Thanks to the robust results from Voxcan, that the JTA-004 trial has been recently approved by regulatory authorities in Denmark and Bone therapeutics is now ready to initiate its clinical trials.